Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Top 2022 priorities for Novartis 1 Successful launches: Leqvio®, KesimptaⓇ, 177 Lu-PSMA-617, ScemblixⓇ 2 Maintain growth momentum: YCE AZ K KL 3 Progress pipeline: 20+ assets with significant sales potential, approval by 2026, on track 4 Optimize portfolio: Sandoz review, update end 2022; disciplined BD 50 Deliver returns: Continue productivity initiatives, especially manufacturing, business services 6 Reinforce foundations: Culture to drive performance, data science to drive value, ESG leadership 23 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation